HC Wainwright & Co. reiterated coverage on Dynavax Technologies with a new price target
$DVAX
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. reiterated coverage of Dynavax Technologies with a rating of Buy and set a new price target of $20.00 from $16.00 previously